KAKUYASU GROUP CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,116 JPY | -0.14% |
|
-2.67% | +20.91% |
| 2023 | Kakuyasu Group Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 | CI |
| 2021 | COSMOS Pharmaceutical : Topix closes at near one-month high as investors await earnings | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- With a P/E ratio at 10.67 for the current year and 9.91 for next year, earnings multiples are highly attractive compared with competitors.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.2 for the 2024 fiscal year.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Weaknesses
- The company has insufficient levels of profitability.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Sector: Food Retail & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +20.91% | 130M | - | ||
| +0.58% | 6.2B | C | ||
| -4.05% | 365M | - | - | |
| -2.02% | 315M | - | - | |
| +2.30% | 219M | - | - | |
| -22.37% | 162M | - | - | |
| +9.89% | 102M | - | - | |
| -16.45% | 64.79M | - | - | |
| -26.19% | 52.68M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
-
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 7686 Stock
- Ratings Kakuyasu Group Co., Ltd.